Advanced search
Publication Cover
Current Medical Research and Opinion Volume 36, 2020 - Issue 3
Submit an article Journal homepage
403
Views
0
CrossRef citations to date
0
Altmetric
Health Economics

Real-world healthcare resource utilization in patients with indolent non-Hodgkin lymphoma: differences between patients treated with first-line ibrutinib or bendamustine + rituximab

Debra E. IrwinIBM Watson Health, Cambridge, MA, USA; Correspondence[email protected]
,
Kathleen WilsonIBM Watson Health, Cambridge, MA, USA;
,
Gerard HoehnTeva Pharmaceuticals Inc, North Wales, PA, USA
,
Stella MinIBM Watson Health, Cambridge, MA, USA;
&
Erika SzaboTeva Pharmaceuticals Inc, North Wales, PA, USA
Pages 439-444 | Received 10 Sep 2019, Accepted 19 Dec 2019, Published online: 20 Jan 2020

References

  • SEER Stat Fact Sheets: Non-Hodgkin Lymphoma (NHL): National Cancer Institute [Internet]. [cited 2020 Jan 9]. Available from: https://seer.cancer.gov/statfacts/html/nhl.html.
  • American Cancer Society. Cancer facts & figures [Internet]. [cited 2020 Jan 9]. Available from: http://www.cancer.org/Research/CancerFactsStatistics/cancerfactsfigures2016/cancerfactsandfigures2016.
  • Leukemia & Lymphoma Society. Non-Hodgkin lymphoma [Internet]. [cited 2020 Jan 9]. Available from: https://www.lls.org/lymphoma/non-hodgkin-lymphoma.
  • Cho SF, Wu WH, Yang YH, et al. Investigation of treatment pattern, medical resource utilization and demographic prognostic factors in older patients with non-Hodgkin lymphoma: a nationwide population-based study. J Geriatr Oncol. 2018;9(4):315–320.
  • Ren J, Asche CV, Shou Y, et al. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. J Comp Eff Res. 2019;8(6):393–402.
  • Morrison VA, Bell JA, Hamilton L, et al. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. Future Oncol (London, England). 2018;14(25):2627–2642.
  • Bonafede M, Feliciano J, Cai Q, et al. Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure. CEOR. 2018;10:629–641.
  • Reyes C, Engel-Nitz NM, DaCosta Byfield S, et al. Cost of disease progression in patients with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkin's lymphoma. Oncologist. 2019;24(9):1219–1228.
  • Beveridge R, Satram-Hoang S, Sail K, et al. Economic impact of disease progression in follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2011;52(11):2117–2123.
  • Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet (London, England). 2012;380(9844):848–857.
  • TREANDA®. TREANDA® (bendamustine hydrochloride) prescribing information. Revised March 2015. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2015.
  • Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet (London, England). 2013;381(9873):1203–1210.
  • Mondello P, Steiner N, Willenbacher W, et al. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. Ann Hematol. 2016;95(7):1107–1114.
  • The role of front-line bendamustine plus rituximab in indolent NHL and MCL. ASCO Annual Meeting (2017) 2017.
  • Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952.
  • IMBRUVICA®. IMBRUVICA® (ibrutinib) prescribing information. Revised May 2016. Sunnyvale, CA: Pharmacyclics; 2016.
  • Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–2506.
  • O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48–58.
  • Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
  • Barr P, Robak T, Owen CJ, et al. Updated efficacy and safety from the phase 3 resonate-2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. Blood. 2016;128(22):234–234.
  • Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med. 2015;372(15):1430–1440.
  • Treon SP, Gustine J, Meid K, et al. Ibrutinib is highly active as first line therapy in symptomatic Waldenstrom's macroglobulinemia. Blood. 2017;130(Suppl 1):2767.
  • Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–2232.
  • FDA approves imbruvica (ibrutinib) for the first-line treatment of chronic lymphocytic leukemia [Internet]. Drugs.com. [cited 2018 Apr 11]. Available from: https://www.drugs.com/newdrugs/fda-approves-imbruvica-ibrutinib-first-line-chronic-lymphocytic-leukemia-4353.html.
  • U.S. FDA approves imbruvica (ibrutinib) as first treatment specifically indicated for relapsed/refractory marginal zone lymphoma (MZL) [Internet]. [cited 2020 Jan 9]. Available from: https://www.drugs.com/newdrugs/u-s-fda-approves-imbruvica-ibrutinib-first-specifically-indicated-relapsed-refractory-marginal-zone-4476.html.
  • Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258–1267.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.